PON1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL68260	0.66	3/20
SCHEMBL5881481	0.64	3/20
SCHEMBL19353901	0.64	3/20
SCHEMBL15245384	0.61	3/20
SCHEMBL12473502	0.60	3/20
SCHEMBL1209429	0.58	3/20
SCHEMBL5969658	0.58	3/20
SCHEMBL9277841	0.51	3/20
SCHEMBL523848	0.50	3/20
SCHEMBL11297595	0.50	3/20
SCHEMBL20588779	0.50	3/20
SCHEMBL6226762	0.49	3/20
SCHEMBL8368021	0.47	3/20
Hydrochloric Acid (SCHEMBL556929)	0.37	3/20
SCHEMBL9275537	0.72	2/20
4,5,7-Trimethyl-2H-Chromen-2-One (SCHEMBL18096558)	0.66	2/20
Hydrochloric Acid (SCHEMBL23698409)	0.58	2/20
SCHEMBL1076978	0.57	2/20
SCHEMBL5304277	0.56	2/20
Bromide (SCHEMBL15819609)	0.55	2/20

Clinical trials — most relevant to PON1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism	PHASE4	COMPLETED
The HDL Particle Protection Study	PHASE4	COMPLETED
Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents.	PHASE4	UNKNOWN
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients	PHASE4	COMPLETED
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes	PHASE2/PHASE3	COMPLETED
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors	PHASE1	RECRUITING
Retinoic Acid Supplementation and Subjects With Hypercholesterolemia	EARLY_PHASE1	COMPLETED
The Effect of Manual Lymph Drainage in Fibromyalgia Patients	EARLY_PHASE1	ENROLLING_BY_INVITATION
Rosuvastatin (Crestor) in Friedreich Ataxia	EARLY_PHASE1	COMPLETED
Serum Oxidative Status as a Potential Predictor of Coronary Artery Disease.	nan	UNKNOWN
Paraoxonase and HDL Qualities in Glycaemia and Inflammation	nan	RECRUITING
Paraoxonase and LDL Oxidation in Carotid Artery Disease	nan	COMPLETED
Paraoxanase Enzyme Activity in Patients With Pulmonary Diseases	nan	COMPLETED
The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque	nan	UNKNOWN
Decrease in Paraoxonase Enzyme Level and Myocardial İnfarction	nan	COMPLETED
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies	nan	COMPLETED
Paraoxonase-1 Pseudo Cholinesterase Organophosphate Toxicity Enzyme in Prediction the Severity and Outcome of Acute Organophosphate Poisoning and Its Correlation With Pseudo Cholinesterase Enzyme Level.	nan	UNKNOWN
HDL Function Dietary Supplement Safety and QOL	nan	UNKNOWN
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS	nan	COMPLETED
The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism	nan	COMPLETED
Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors	nan	COMPLETED
Diabetic Cardiomyopathy and Heart Failure	nan	WITHDRAWN
the Change of Cholesterol Efflux Capacity and Coronary Artery Disease in Real Clinical Practice	nan	UNKNOWN
The Role of Dysfunctional HDL in Severe Sepsis	nan	COMPLETED
Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease	nan	COMPLETED
Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification	nan	COMPLETED
Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD	nan	RECRUITING
Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase.	nan	UNKNOWN
Novel Cardiovascular Biomarkers in Patients With Kidney Disease	nan	NOT_YET_RECRUITING
Metabolism and Body Shape of Healthy Children and Children With Chronic Infections	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PON1 binder may also engage these)

Protein	Name	Similarity
P27170	—	1.000	P27170 →
Q6AXM8	—	0.998	Q6AXM8 →
P52430	—	0.998	P52430 →
Q58DS7	—	0.995	Q58DS7 →
P55159	—	0.994	P55159 →
Q62086	—	0.993	Q62086 →
Q15165	—	0.988	Q15165 →
Q9BGN0	—	0.986	Q9BGN0 →
Q68FP2	—	0.986	Q68FP2 →
Q15166	—	0.985	Q15166 →
P54832	—	0.983	P54832 →
Q62087	—	0.981	Q62087 →
Q90952	—	0.977	Q90952 →
Q91090	—	0.977	Q91090 →
B5X3B2	—	0.971	B5X3B2 →
Q803F5	—	0.962	Q803F5 →
Q7TP48	—	0.959	Q7TP48 →
Q5ZIF1	—	0.956	Q5ZIF1 →
APMAP	Adipocyte plasma membrane-associated protein	0.956	landscape →
Q9D7N9	—	0.951	Q9D7N9 →
COMT	Catechol O-methyltransferase	0.949	landscape →
P22734	—	0.948	P22734 →
Q58CQ9	—	0.948	Q58CQ9 →
Q08C93	—	0.947	Q08C93 →
Q3T0E5	—	0.946	Q3T0E5 →
P54281	—	0.944	P54281 →
Q5F477	—	0.943	Q5F477 →
Q9QX15	—	0.943	Q9QX15 →
Q9NX78	—	0.942	Q9NX78 →
Q5H879	—	0.942	Q5H879 →